Drug shortage
Tazemetostat Hydrobromide Tablet · Epizyme, Inc. (An Ipsen Company)
FDA drug shortage · To Be Discontinued · updated Mar 27, 2026
Key facts
| Generic name | Tazemetostat Hydrobromide Tablet |
|---|---|
| Company | Epizyme, Inc. (An Ipsen Company) |
| Presentation | Tazverik, Tablet, 200 mg (NDC 72607-100-00) |
| Dosage form | Tablet |
| Status | To Be Discontinued |
| Therapeutic category | Oncology |
| Package NDCs | 72607-100-00 |
| First posted | Mar 27, 2026 |
| Last updated | Mar 27, 2026 |
| Discontinued | Mar 27, 2026 |
At a glance
- 1–9 Package NDCs affected
- 1–9 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: